AB170922

Anti-FGL1 antibody [EPR9937]

KO Validated
RabMAb
Recombinant
각 태그의 뜻

Be the first to review this product! 리뷰 제출

(3 제품이 사용된 논문 )

Rabbit Recombinant Monoclonal FGL1 antibody. Suitable for IP, WB and reacts with Human samples. Cited in 3 publications.

대체 명칭 보기

HFREP1, FGL1, Fibrinogen-like protein 1, HP-041, Hepassocin, Hepatocyte-derived fibrinogen-related protein 1, Liver fibrinogen-related protein 1, HPS, HFREP-1, LFIRE-1

3 이미지

Supplier Data

Immunoprecipitation - Anti-FGL1 antibody [EPR9937] (AB170922)

All lanes:

Immunoprecipitation - Anti-FGL1 antibody [EPR9937] (ab170922) at 1/1000 dilution

All lanes:

Immunoprecipitation pellet from Human fetal liver lysate using ab170922 at 1/10. at 10 µg

Secondary

All lanes:

Goat anti-rabbit HRP conjugated antibody at 1/2000 dilution

Predicted band size: 36 kDa

Observed band size: ~50 kDa

true

Lab

Western blot - Anti-FGL1 antibody [EPR9937] (AB170922)

Western blot : Rabbit Monoclonal [EPR9937] to FGL1 ab170922 staining at 1/1000 dilution, shown in green; Mouse anti alpha Tubulin ab7291 loading control staining at 1/20000 dilution, shown in magenta. A band was observed at 36 kDa. To generate this image, samples were run on an SDS-PAGE gel then transferred onto a nitrocellulose membrane. Membranes were blocked in 3pc Milk in TBS-0.1 % Tween 20 (TBS-T) before incubation with primary antibodies overnight at 4 C. Blots were washed four times in TBS-T, incubated with secondary antibodies for 1 h at room temperature, washed again four times then imaged. Secondary antibodies used were Goat anti-Rabbit 800CW and Goat anti-Mouse 680RD at 1/20,000 dilution.

All lanes:

Western blot - Anti-FGL1 antibody [EPR9937] (ab170922) at 1/1000 dilution

Lane 1:

Wild-type A549 IL-6 (5 ng/mL, 48 h) + BFA (5 g/mL, last 6 h) at 20 µg

Lane 2:

Wild-type A549 IL-6 (0 ng/mL, 48 h) + BFA (5 g/mL, last 6 h) at 20 µg

Lane 3:

Wild-type A549 BFA (0 g/mL, 6 h) at 20 µg

Lane 4:

FGL1 knockout A549 IL-6 (5 ng/mL, 48 h) + BFA (5 g/mL, last 6 h) at 20 µg

Lane 5:

FGL1 knockout A549 IL-6 (0 ng/mL, 48 h) + BFA (5 g/mL, last 6 h) at 20 µg

Lane 6:

FGL1 knockout A549 BFA (0 g/mL, 6 h) at 20 µg

Lane 7:

HepG2 at 20 µg

Lane 8:

HeLa at 20 µg

Secondary

All lanes:

Goat anti-Rabbit 800CW & Goat anti-Mouse 680RD at 1/20000 dilution

Predicted band size: 36 kDa

Observed band size: 36 kDa

false

Supplier Data

Western blot - Anti-FGL1 antibody [EPR9937] (AB170922)

All lanes:

Western blot - Anti-FGL1 antibody [EPR9937] (ab170922) at 1/1000 dilution

Lane 1:

Human fetal liver lysate at 10 µg

Lane 2:

HepG2 cell lysate at 10 µg

Secondary

All lanes:

Goat anti-rabbit HRP conjugated antibody at 1/2000 dilution

Predicted band size: 36 kDa

true

주요 정보

Host species

Rabbit

Clonality

Monoclonal

Clone number

EPR9937

Isotype

IgG

Carrier free

Reacts with

Human

Applications

IP, WB

applications

Immunogen

The exact immunogen used to generate this antibody is proprietary information.

style

left-column

style

left-column

Reactivity 정보

{ "title": "Reactivity Data", "filters": { "stats": ["", "Species", "Dilution Info", "Notes"], "tabs": { "all-applications": {"fullname" : "All Applications", "shortname": "All Applications"}, "IP" : {"fullname" : "Immunoprecipitation", "shortname":"IP"}, "FlowCyt" : {"fullname" : "Flow Cytometry", "shortname":"Flow Cyt"}, "WB" : {"fullname" : "Western blot", "shortname":"WB"}, "IHCP" : {"fullname" : "Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections)", "shortname":"IHC-P"}, "ICCIF" : {"fullname" : "Immunocytochemistry/ Immunofluorescence", "shortname":"ICC/IF"} }, "product-promise": { "all": "all", "testedAndGuaranteed": "tested", "guaranteed": "expected", "predicted": "predicted", "notRecommended": "not-recommended" } }, "values": { "Human": { "IP-species-checked": "testedAndGuaranteed", "IP-species-dilution-info": "1/10 - 1/100", "IP-species-notes": "", "FlowCyt-species-checked": "notRecommended", "FlowCyt-species-dilution-info": "", "FlowCyt-species-notes": "", "WB-species-checked": "testedAndGuaranteed", "WB-species-dilution-info": "1/1000 - 1/5000", "WB-species-notes": "", "IHCP-species-checked": "notRecommended", "IHCP-species-dilution-info": "", "IHCP-species-notes": "", "ICCIF-species-checked": "notRecommended", "ICCIF-species-dilution-info": "", "ICCIF-species-notes": "" }, "Mouse": { "IP-species-checked": "notRecommended", "IP-species-dilution-info": "1/10 - 1/100", "IP-species-notes": "", "FlowCyt-species-checked": "notRecommended", "FlowCyt-species-dilution-info": "", "FlowCyt-species-notes": "", "WB-species-checked": "notRecommended", "WB-species-dilution-info": "1/1000 - 1/5000", "WB-species-notes": "", "IHCP-species-checked": "notRecommended", "IHCP-species-dilution-info": "", "IHCP-species-notes": "", "ICCIF-species-checked": "notRecommended", "ICCIF-species-dilution-info": "", "ICCIF-species-notes": "" }, "Rat": { "IP-species-checked": "notRecommended", "IP-species-dilution-info": "1/10 - 1/100", "IP-species-notes": "", "FlowCyt-species-checked": "notRecommended", "FlowCyt-species-dilution-info": "", "FlowCyt-species-notes": "", "WB-species-checked": "notRecommended", "WB-species-dilution-info": "1/1000 - 1/5000", "WB-species-notes": "", "IHCP-species-checked": "notRecommended", "IHCP-species-dilution-info": "", "IHCP-species-notes": "", "ICCIF-species-checked": "notRecommended", "ICCIF-species-dilution-info": "", "ICCIF-species-notes": "" } } }

style

left-column

제품 세부 정보

Patented technology
Our RabMAb^® technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to RabMAb^® patents.

What are the advantages of a recombinant monoclonal antibody?
This product is a recombinant monoclonal antibody, which offers several advantages including:

- High batch-to-batch consistency and reproducibility
- Improved sensitivity and specificity
- Long-term security of supply
- Animal-free batch production

For more information, read more on recombinant antibodies.

style

left-column

특성 및 보관 정보

제형

Liquid

Purification 테크닉

Affinity purification Protein A

보관 버퍼

pH: 7.2 - 7.4 Preservative: 0.01% Sodium azide Constituents: PBS, 40% Glycerol (glycerin, glycerine), 0.05% BSA

배송 시 보관 조건

Conditional Ambient

적절한 단기 보관 기간

1-2 weeks

적절한 단기 보관 조건

+4°C

적절한 장기 보관 조건

-20°C

분주 정보

Upon delivery aliquot

보관 정보

Avoid freeze / thaw cycle

style

left-column

추가 정보

This supplementary information is collated from multiple sources and compiled automatically.

Fibrinogen-like protein 1 (FGL1) also known as Hepassocin plays a significant role in modulating immune responses. FGL1 is a member of the fibrinogen family with a molecular mass of approximately 31 kDa. This protein is widely expressed in the liver and is also found in other tissues like the pancreas and lungs. Its structural homology to fibrinogen suggests potential binding capabilities with similar ligands influencing its mechanical actions in cellular processes.

Biological function summary

FGL1 modulates the immune system and maintains its homeostasis. It functions primarily as a ligand for the immune checkpoint receptor LAG-3. This FGL1-LAG-3 interaction inhibits T-cell activity leading to immune tolerance and helping prevent autoimmunity. FGL1 while not a part of a complex demonstrates significant standalone biological activity by affecting immune responses especially under pathological conditions.

Pathways

FGL1 integrates into the immune regulatory framework. It exerts its effects mainly through the immune checkpoint pathway impacting T-cell regulation. In addition to LAG-3 FGL1 interacts closely with the PD-1/PD-L1 pathway which is also important in checkpoint inhibition and immune evasion mechanisms. These pathways together orchestrate the immune surveillance system and play roles in maintaining immune equilibrium.

FGL1 has received attention in cancer particularly in its role of suppressing anti-tumor immunity. Its interaction with LAG-3 makes it a potential target for cancer immunotherapy as high FGL1 levels correlate with poor prognosis in various cancers. Additionally it has implications in autoimmune diseases where its regulation of T-cell activity prevents excessive immune responses. By modulating LAG-3 activity FGL1 emerges as a therapeutic target of interest in autoimmune conditions presenting new opportunities for managing such disorders.

style

left-column

style

left-column

제품 프로토콜

For this product, it's our understanding that no specific protocols are required. You can visit:

Visit the General protocols
Visit the Troubleshooting

style

left-column

타겟 정보

Immune suppressive molecule that inhibits antigen-specific T-cell activation by acting as a ligand of LAG3 (PubMed : 30580966, PubMed : 35761082, PubMed : 40101708). LAG3-binding initiates a signaling that inhibits the T-cell receptor (TCR) in the immunological synapse, preventing T-cell activation (PubMed : 30580966). Binds LAG3 independently from MHC class II (MHC-II) (PubMed : 30580966, PubMed : 35761082). Secreted by, and promotes growth of, hepatocytes (PubMed : 11470158, PubMed : 19880967).

See full target information FGL1

style

left-column

제품이 사용된 논문 (3)

Recent publications for all applications. Explore the 전체 목록 and refine your search

Acta pharmacologica Sinica 45:1951-1963 PubMed38760543

2024

Bevacizumab induces ferroptosis and enhances CD8 T cell immune activity in liver cancer via modulating HAT1 and increasing IL-9.

Applications

Unspecified application

Species

Unspecified reactive species

Chun-Yu Hou,Pan Lv,Hong-Feng Yuan,Li-Na Zhao,Yu-Fei Wang,Hui-Hui Zhang,Guang Yang,Xiao-Dong Zhang

Frontiers in immunology 13:1014053 PubMed36268014

2022

Dual immunological and proliferative regulation of immune checkpoint FGL1 in lung adenocarcinoma: The pivotal role of the YY1-FGL1-MYH9 axis.

Applications

Unspecified application

Species

Unspecified reactive species

Xi-Yang Tang,Yan-Lu Xiong,Ya-Bo Zhao,Jie Yang,An-Ping Shi,Kai-Fu Zheng,Yu-Jian Liu,Chen Shu,Tao Jiang,Nan Ma,Jin-Bo Zhao

Human mutation 43:42-55 PubMed34816548

2021

GGCX variants leading to biallelic deficiency to γ-carboxylate GRP cause skin laxity in VKCFD1 patients.

Applications

Unspecified application

Species

Unspecified reactive species

Suvoshree Ghosh,Katrin Kraus,Arijit Biswas,Jens Müller,Francesco Forin,Heike Singer,Klara Höning,Veit Hornung,Matthias Watzka,Johannes Oldenburg,Katrin J Czogalla-Nitsche

제품이 사용된 논문 모두 보기

style

left-column

style

left-column

style

right-column

Product promise

저희는 고품질 시약으로 고객님의 연구를 서포트하고자 최선을 다하고 있으며, 모든 단계에서 함께 하겠습니다. 만약 제품이 기대한 성능을 보이지 않을 경우에도 Product Promise로 보호받으실 수 있습니다.

자세한 내용은 이용 약관을 확인해 주세요.

Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.

For licensing inquiries, please contact partnerships@abcam.com

Anti-FGL1 antibody [EPR9937]

Immunoprecipitation - Anti-FGL1 antibody [EPR9937] (AB170922)

Western blot - Anti-FGL1 antibody [EPR9937] (AB170922)

Western blot - Anti-FGL1 antibody [EPR9937] (AB170922)

관련 conjugated 항체와 다양한 조성의 항체 (1)

주요 정보

Host species

Clonality

Clone number

Isotype

Carrier free

Reacts with

Applications

Immunogen

대체품

Primary Antibodies

Primary Antibodies

보완 제품

Assay Kits

Primary Antibodies

Primary Antibodies

Primary Antibodies

Primary Antibodies

Reactivity 정보

제품 세부 정보

특성 및 보관 정보

제형

Purification 테크닉

보관 버퍼

배송 시 보관 조건

적절한 단기 보관 기간

적절한 단기 보관 조건

적절한 장기 보관 조건

분주 정보

보관 정보

추가 정보

Biological function summary

Pathways

제품 프로토콜

타겟 정보

제품이 사용된 논문 (3)

Product promise